Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
ATRAAtara Biotherapeutics(ATRA) Zacks Investment Research·2024-05-10 06:16

Atara Biotherapeutics (ATRA) came out with a quarterly loss of 0.23pershareversustheZacksConsensusEstimateofalossof0.23 per share versus the Zacks Consensus Estimate of a loss of 0.37. This compares to loss of 0.72pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof37.840.72 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 37.84%. A quarter ago, it was expected that this drug developer would post a loss of 0.61 per share when it actually produced a loss of $0.56, delivering a surprise of 8.20%. Over the last four quarters, the compan ...